Frontiers in Oncology (Jul 2021)
Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia
- Xiaoya Yun,
- Xiaoya Yun,
- Xiaoya Yun,
- Xiaoya Yun,
- Xiaoya Yun,
- Xiaoya Yun,
- Xiang Sun,
- Xiang Sun,
- Xiang Sun,
- Xiang Sun,
- Xiang Sun,
- Xiang Sun,
- Xinting Hu,
- Xinting Hu,
- Xinting Hu,
- Xinting Hu,
- Xinting Hu,
- Xinting Hu,
- Huimin Zhang,
- Huimin Zhang,
- Huimin Zhang,
- Huimin Zhang,
- Huimin Zhang,
- Huimin Zhang,
- Zixun Yin,
- Zixun Yin,
- Zixun Yin,
- Zixun Yin,
- Zixun Yin,
- Zixun Yin,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang,
- Ming Liu,
- Ming Liu,
- Ming Liu,
- Ming Liu,
- Ming Liu,
- Ming Liu,
- Ya Zhang,
- Ya Zhang,
- Ya Zhang,
- Ya Zhang,
- Ya Zhang,
- Ya Zhang,
- Xin Wang,
- Xin Wang,
- Xin Wang,
- Xin Wang,
- Xin Wang,
- Xin Wang
Affiliations
- Xiaoya Yun
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xiaoya Yun
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xiaoya Yun
- School of Medicine, Shandong University, Jinan, China
- Xiaoya Yun
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Xiaoya Yun
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Xiaoya Yun
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xiang Sun
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xiang Sun
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xiang Sun
- School of Medicine, Shandong University, Jinan, China
- Xiang Sun
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Xiang Sun
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Xiang Sun
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xinting Hu
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xinting Hu
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xinting Hu
- School of Medicine, Shandong University, Jinan, China
- Xinting Hu
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Xinting Hu
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Xinting Hu
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Huimin Zhang
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Huimin Zhang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Huimin Zhang
- School of Medicine, Shandong University, Jinan, China
- Huimin Zhang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Huimin Zhang
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Huimin Zhang
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Zixun Yin
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Zixun Yin
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Zixun Yin
- School of Medicine, Shandong University, Jinan, China
- Zixun Yin
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Zixun Yin
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Zixun Yin
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xin Zhang
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xin Zhang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xin Zhang
- School of Medicine, Shandong University, Jinan, China
- Xin Zhang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Xin Zhang
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Xin Zhang
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Ming Liu
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Ming Liu
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Ming Liu
- School of Medicine, Shandong University, Jinan, China
- Ming Liu
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Ming Liu
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Ming Liu
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Ya Zhang
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Ya Zhang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Ya Zhang
- School of Medicine, Shandong University, Jinan, China
- Ya Zhang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Ya Zhang
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Ya Zhang
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xin Wang
- Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
- Xin Wang
- Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Xin Wang
- School of Medicine, Shandong University, Jinan, China
- Xin Wang
- Shandong Provincial Engineering Research Center of Lymphoma, Jinan, China
- Xin Wang
- Branch of National Clinical Research Center for Hematologic Diseases, Jinan, China
- Xin Wang
- National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
- DOI
- https://doi.org/10.3389/fonc.2021.698572
- Journal volume & issue
-
Vol. 11
Abstract
Lipid metabolism is related to lymphomagenesis, and is a novel therapeutic target in some hematologic tumors. Apolipoprotein A (ApoA), the major protein of high-density lipoprotein (HDL), plays a crucial role in lipid transportation and protecting against cardiovascular disease, and takes effect on anti-inflammation and anti-oxidation. It is correlated with the prognosis of some solid tumors. Yet, there is no investigation involving the role of ApoA plays in chronic lymphocytic leukemia (CLL). Our retrospective study focuses on the prognostic value of ApoA in CLL and its therapeutic potential for CLL patients. Herein, ApoA is a favorable independent prognostic factor for both overall survival (OS) and progression-free survival (PFS) of CLL patients. ApoA is negatively associated with β2-microglobulin (β2-MG) and advanced stage, which are poor prognostic factors in CLL. Age, Rai stage, ApoA, and adenosine deaminase (ADA) are included in a new risk scoring system named ARAA-score. It is capable of assessing OS and PFS of CLL patients. Furthermore, cell proliferation assays show that the ApoA-I mimetic L-4F can inhibit the proliferation of CLL cell lines and primary cells. In conclusion, ApoA is of prognostic value in CLL, and is a potential therapy for CLL patients. The ARAA-score may optimize the risk stratification of CLL patients.
Keywords
